MBRX Moleculin Biotech, Inc.
$9.27▲ +30.77%
Healthcare
Other
After hours
$9.70▲ +4.68%
Oct 27, 5:39 PM ET
Volume 183.7K
Avg Volume (10D) 43.7K
Key Metrics & Fundamentals
Market Cap
$9.44M
P/E Ratio
0.1
Div Yield
0.00%
52W Range
3.22 - 315.00
% vs 50 MA
-15.29%
% vs 200 MA
-77.66%
RSI-14
51.5
MACD Histogram
+0.4200
Beta (1Y vs SPY)
5.59
Free Cash Flow
-$6.66M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$7.54M
COGS
–
Operating Exp
$7.56M
Operating Income
-$7.56M
EBIT
-$7.56M
Pretax Income
-$7.64M
Net Income
-$7.64M
EPS (Diluted)
-1.40
Price & Volume History
Loading chart…
Recent News
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
GlobeNewswire · Oct 20, 2026 8:12 AM ET
Moleculin Announces Reverse Stock Split
GlobeNewswire · Oct 16, 2026 9:20 AM ET
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
GlobeNewswire · Oct 7, 2026 8:45 AM ET
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
GlobeNewswire · Sep 29, 2026 8:45 AM ET
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
GlobeNewswire · Sep 28, 2026 7:00 AM ET
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
GlobeNewswire · Sep 25, 2026 1:05 PM ET
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
GlobeNewswire · Sep 23, 2026 8:25 AM ET
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
GlobeNewswire · Sep 14, 2026 8:35 AM ET
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
GlobeNewswire · Sep 11, 2026 8:30 AM ET
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
GlobeNewswire · Aug 27, 2026 9:01 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See MBRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.